ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QTTB / earnings
RCKT (28) BIOA (31) LYEL (30) LRMR (34) ⌘ Pro Terminal →

Q32 Bio Inc. (QTTB) Next Earnings Date & Expected ±12.5% Move

$8.71 -2.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.66

Q32 Bio Inc. (QTTB) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $265.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QTTB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QTTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Q32 Bio Inc. (NASDAQ: QTTB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.71 (-2.24% 1D, market cap $265.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, QTTB ranks #236 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QTTB compare to RCKT and BIOA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QTTB carries a Roarable D+ (53/100 RQD), trailing P/E of 8.9x, gross margin of —, and ROIC of 85.0%. By comparison, RCKT (Rocket Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M) and BIOA (BioAge Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QTTB?
▼

Per QTTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661998), Q32 Bio Inc. generated $53.7M in revenue (-71.0% YoY), $29.8M in net income, and -$33.5M in free cash flow against $61.8M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.66 (-0.59%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C
Cash (12)Whales (6)SEC (16)Macro (9)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$25 Bull$9 Base$7 Bear
📬 FREE QTTB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTTB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY QTTB SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)

Altman Z-Score 5.99 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$8.06+6.9% Next Q
Q2 (-2Q)
48
Grade D$8.62+1% Next Q
Q3 (-1Q)
50
Grade C-$8.71+0% Next Q
Current
53
Grade D+$8.71-0.9% Hist 90D α
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QTTB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QTTB currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.16) and Max Pain ($9.15) forces dealer call-delta covering toward $24.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTTB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QTTB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.09 Expected Swing
$7.62 (-12.5%)Spot $8.71$9.80 (+12.5%)
MODEL EARNINGS SETUP GAUGE

QTTB Quantitative Pre-Earnings Setup: 53/100

Trailing EPS: $1.00 • YoY Revenue Growth: 12.4%

Model Bullish Setup (53/100)Model Risk Weight (47/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$53.7M$29.8M-$33.5M52%
FY 20242024-12-31$185.1M-$47.7M-$67.8M52%
FY 20232023-12-31$1.2M-$53.7M-$18.7M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTTB)

  • ✓Walkthrough of QTTB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QTTB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +72.82%⚡ TESTING RESISTANCE
2026-11-03O $8.87H $8.91L $8.71C $8.71VOL 268.2K
RES: $8.85SUP: $6.67SMA50: $10.16SMA200: $9.29
$24.97$19.16$13.34$7.53$1.72RES $8.85SUP $6.67$8.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QTTB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QTTB Butterfly Map → + Track QTTB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-3.4%/yr Implied 5Y Growth

vs. -71.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QTTB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QTTB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTTB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTTB)

Health Care Rank #236 of 1015 ⚔️ RCKT vs QTTB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QTTB vs. RCKT, BIOA, LYEL, LRMR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Q32 Bio Inc. (QTTB) ranks #236 by composite RQD confidence (53/100, grade D+) and #531 by equity capitalization ($265.2M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QTTB ACTIVE
Q32 Bio Inc.
D+ 53/100 8.9x — 85.0% -2.24% $265.2M Benchmark Subject
RCKT
Rocket Pharmaceuticals Inc.
E 28/100 — — -35.0% +1.23% $267.9M /rckt-vs-qttb →
BIOA
BioAge Labs Inc.
E 31/100 — — -35.0% -1.19% $269.4M /bioa-vs-qttb →
LYEL
Lyell Immunopharma Inc.
E 30/100 — — -35.0% -1.45% $270.5M /lyel-vs-qttb →
LRMR
Larimar Therapeutics Inc.
E 34/100 — — -35.0% -4.05% $256.6M /lrmr-vs-qttb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661998 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Q32 Bio Inc. (QTTB) reported GAAP revenue of $53.7M (-71.0% vs. FY2024 revenue of $185.1M , and +4548.5% cumulative change since FY2023) , GAAP net income of $29.8M, operating cash flow of -$33.5M, and free cash flow of -$33.5M (+50.5% YoY). On the balance sheet, QTTB closed FY2025 with $61.8M in total assets against $0 in total debt (Altman Z-Score: 5.99, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $53.7M $29.8M -$33.5M -$33.5M $61.8M —
FY2024 (FY) 2024-12-31 $185.1M -$47.7M -$67.7M -$67.8M $92.3M —
FY2023 (FY) 2023-12-31 $1.2M -$53.7M -$18.7M -$18.7M — —

3. QTTB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QTTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Q32 Bio Inc. (NASDAQ: QTTB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.71 (-2.24% 1D, market cap $265.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, QTTB ranks #236 in composite RQD confidence.

How does QTTB compare to RCKT and BIOA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QTTB carries a Roarable D+ (53/100 RQD), trailing P/E of 8.9x, gross margin of —, and ROIC of 85.0%. By comparison, RCKT (Rocket Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M) and BIOA (BioAge Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QTTB?

Per QTTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661998), Q32 Bio Inc. generated $53.7M in revenue (-71.0% YoY), $29.8M in net income, and -$33.5M in free cash flow against $61.8M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QTTB trading relative to its 50-day, 200-day, and 52-week technical levels?

QTTB last traded at $8.71 (-2.24% on volume of 246,708 shares), positioning the stock -14.27% below its 50-day simple moving average ($10.16) and -6.24% below its 200-day simple moving average ($9.29). Across its 52-week range of $1.90 to $23.57, QTTB sits at the 31.4% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.62 to $9.80).

Direct Sub-Reports: QTTB RQD Cockpit QTTB 12M Forecast QTTB Earnings & Move QTTB Dividends & DRIP QTTB Insiders & 13F QTTB Whale Options QTTB Profit Sankey QTTB News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

QTTB — Q32 Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Q32 Bio Inc. (QTTB) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $8.71 (-2.24% 1D, market capitalization $265.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of —, operating margin of 31.5%, and free cash flow yield of -12.70%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.99, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Q32 Bio Inc. (QTTB) is listed on NASDAQ and sits in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile describes it as an issuer with a market capitalization of $0.3B. The sources do not describe its products, customers, or revenue model. Revenue details are available only as reported financial figures (see Financial Trend).

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Q32 Bio Inc. (QTTB) reported $53.7M in annual revenue (up from $185.1M in FY2024, -71.0% YoY) and $29.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2M revenue, -$53.7M net income) through FY2025, QTTB scaled operating cash flow to -$33.5M and free cash flow to -$33.5M, backed by $61.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -12.70% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $1.90 – $23.57 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 8.9x trailing P/E and 12.8x EV/EBITDA against 31.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), QTTB carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can QTTB sustain or expand its 31.5% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $53.7M and free cash flow of -$33.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QTTB's 8.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QTTB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Q32 Bio Inc. (QTTB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QTTB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QTTB Bull vs. Bear Conversation Board — What's Your Call at $8.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QTTB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QTTB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $10.25 (+15.0%)
📌 Pinned Debate

A 16/20 forensic balance sheet (Altman Z 5.99, Debt/Equity 0.5) and FY 2025 operating income of $16.9M give the company a stronger fina

A 16/20 forensic balance sheet (Altman Z 5.99, Debt/Equity 0.5) and FY 2025 operating income of $16.9M give the company a stronger financial base than its FY 2024 and FY 2023 losses suggested.. When you look under the hood at QTTB, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 85.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $23.57. My 12M target is $10.25.

ArenaChamp_24 🐂 BULL

@MacroHawk_NYC Agree on the RQD 53/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.91 and keeping dry powder in case we test $8.29.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $7.48 (-16.0%)
Spot @ $8.91

FY 2025 free cash flow of -$33.5M and an FCF yield of -12.7% show the reported profits are not yet converting into cash, leaving the Ro

Careful chasing QTTB at $8.91. FY 2025 free cash flow of -$33.5M and an FCF yield of -12.7% show the reported profits are not yet converting into cash, leaving the Roarable rating at D+ with a Sell verdict.. Gross margin is 0.0%, but operating margin is 31.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $7.48 on multiple compression.

LIVE TAPE